{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:32:03Z","timestamp":1793745123055,"version":"4.6.1"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41581-025-01031-3","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:26:12Z","timestamp":1765196772000},"page":"283-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4536-9891","authenticated-orcid":false,"given":"Amanda DeMauro","family":"Renaghan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9500-9080","authenticated-orcid":false,"given":"Marlies","family":"Ostermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ballen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cosmai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Floris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-5309","authenticated-orcid":false,"given":"Lui G.","family":"Forni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-9097","authenticated-orcid":false,"given":"Ilya G.","family":"Glezerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5747-2151","authenticated-orcid":false,"given":"Shruti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4537","authenticated-orcid":false,"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5756-5120","authenticated-orcid":false,"given":"Edgar A.","family":"Jaimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0989-0241","authenticated-orcid":false,"given":"Sabine","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4340-5046","authenticated-orcid":false,"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheron","family":"Latcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7875-090X","authenticated-orcid":false,"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9706-1579","authenticated-orcid":false,"given":"Paolo","family":"Lentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Ma\u0142yszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoka","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Pani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-2659","authenticated-orcid":false,"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4419-6813","authenticated-orcid":false,"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-9675","authenticated-orcid":false,"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-0689","authenticated-orcid":false,"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8211-018X","authenticated-orcid":false,"given":"Ver\u00f4nica","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimda","family":"Wanchoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Whitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biruh T.","family":"Workeneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Zepeda-Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell H.","family":"Rosner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"1031_CR1","unstructured":"American Cancer Society. Cancer Facts & Figures 2024 (American Cancer Society, 2024)."},{"key":"1031_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000049","volume":"2","author":"J Zhao","year":"2023","unstructured":"Zhao, J. et al. Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019. BMJ Oncol. 2, e000049 (2023).","journal-title":"BMJ Oncol."},{"key":"1031_CR3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1053\/j.ajkd.2022.02.020","volume":"80","author":"A Kitchlu","year":"2022","unstructured":"Kitchlu, A. et al. Cancer risk and mortality in patients with kidney disease: a population-based cohort study. Am. J. Kidney Dis. 80, 436\u2013448.e1 (2022).","journal-title":"Am. J. Kidney Dis."},{"key":"1031_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2215\/CJN.0000000000000105","volume":"18","author":"MA Butrovich","year":"2023","unstructured":"Butrovich, M. A. et al. Inclusion of participants with CKD and other kidney-related considerations during clinical drug development: landscape analysis of anticancer agents approved from 2015 to 2019. Clin. J. Am. Soc. Nephrol. 18, 455\u2013464 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1031_CR5","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.2018.7260","volume":"319","author":"A Kitchlu","year":"2018","unstructured":"Kitchlu, A. et al. Representation of patients with chronic kidney disease in trials of cancer therapy. JAMA 319, 2437\u20132439 (2018).","journal-title":"JAMA"},{"key":"1031_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1681\/ASN.2012070690","volume":"24","author":"AK Salahudeen","year":"2013","unstructured":"Salahudeen, A. K. & Bonventre, J. V. Onconephrology: the latest frontier in the war against kidney disease. J. Am. Soc. Nephrol. 24, 26\u201330 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1031_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003467","volume":"9","author":"S Gupta","year":"2021","unstructured":"Gupta, S. et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J. Immunother. Cancer 9, e003467 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1031_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-077169","volume":"384","author":"S Gupta","year":"2024","unstructured":"Gupta, S. et al. Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study. BMJ 384, e077169 (2024).","journal-title":"BMJ"},{"key":"1031_CR9","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1182\/blood.2024026211","volume":"145","author":"S Gupta","year":"2025","unstructured":"Gupta, S. et al. Glucarpidase for treatment of high-dose methotrexate toxicity. Blood 145, 1858\u20131869 (2025).","journal-title":"Blood"},{"key":"1031_CR10","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/ndt\/gfaf004","volume":"40","author":"M Charkviani","year":"2025","unstructured":"Charkviani, M. et al. Incidence of acute kidney injury in relapsed and refractory multiple myeloma treated with teclistamab versus CAR T-cells. Nephrol. Dial. Transpl. 40, 1512\u20131521 (2025).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1031_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000349961","volume":"182","author":"C Ronco","year":"2013","unstructured":"Ronco, C., Kellum, J. A., Bellomo, R. & Mehta, R. L. Acute dialysis quality initiative (ADQI). Contrib. Nephrol. 182, 1\u20134 (2013).","journal-title":"Contrib. Nephrol."},{"key":"1031_CR12","doi-asserted-by":"publisher","unstructured":"Kellum, J. A. et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Suppl. https:\/\/doi.org\/10.1038\/kisup.2012.1 (2012).","DOI":"10.1038\/kisup.2012.1"},{"key":"1031_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.kint.2021.06.028","volume":"100","author":"NH Lameire","year":"2021","unstructured":"Lameire, N. H. et al. Harmonizing acute and chronic kidney disease definition and classification: report of a kidney disease: improving global outcomes (KDIGO) consensus conference. Kidney Int. 100, 516\u2013526 (2021).","journal-title":"Kidney Int."},{"key":"1031_CR14","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMra1613984","volume":"376","author":"MH Rosner","year":"2017","unstructured":"Rosner, M. H. & Perazella, M. A. Acute kidney injury in patients with cancer. N. Engl. J. Med. 376, 1770\u20131781 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1031_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2019.10.025","volume":"72","author":"K Kashani","year":"2020","unstructured":"Kashani, K., Rosner, M. H. & Ostermann, M. Creatinine: from physiology to clinical application. Eur. J. Intern. Med. 72, 9\u201314 (2020).","journal-title":"Eur. J. Intern. Med."},{"key":"1031_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1053\/j.ajkd.2005.08.038","volume":"47","author":"MH Rosner","year":"2006","unstructured":"Rosner, M. H. & Bolton, W. K. Renal function testing. Am. J. Kidney Dis. 47, 174\u2013183 (2006).","journal-title":"Am. J. Kidney Dis."},{"key":"1031_CR17","first-page":"1043","volume":"23","author":"J Chen","year":"2015","unstructured":"Chen, J., Wang, X., Luo, P. & He, Q. Effects of unidentified renal insufficiency on the safety and efficacy of chemotherapy for metastatic colorectal cancer patients: a prospective, observational study. Supportive Care Cancer 23, 1043\u20131048 (2015).","journal-title":"Supportive Care Cancer"},{"key":"1031_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2023.151340","volume":"42","author":"MH Rosner","year":"2022","unstructured":"Rosner, M. H., Sprangers, B., Sandhu, G. & Malyszko, J. Glomerular filtration rate measurement and chemotherapy dosing. Semin. Nephrol. 42, 151340 (2022).","journal-title":"Semin. Nephrol."},{"key":"1031_CR19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.2215\/CJN.0000000000000508","volume":"19","author":"A Kitchlu","year":"2024","unstructured":"Kitchlu, A. et al. Assessment of GFR in patients with cancer: a statement from the American Society of Onco-nephrology. Clin. J. Am. Soc. Nephrol. 19, 1061\u20131072 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1031_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.2215\/CJN.0000000616","volume":"20","author":"SM Titan","year":"2025","unstructured":"Titan, S. M. et al. Performance of creatinine and cystatin-based equations on estimating measured GFR in people with hematological and solid cancers. Clin. J. Am. Soc. Nephrol. 20, 358\u2013366 (2025).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1031_CR21","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2215\/CJN.0000000000000509","volume":"19","author":"A Kitchlu","year":"2024","unstructured":"Kitchlu, A. et al. Assessment of GFR in patients with cancer part 2: anticancer therapies-perspectives from the American Society of Onco-nephrology (ASON). Clin. J. Am. Soc. Nephrol. 19, 1073\u20131077 (2024).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1031_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.kint.2024.06.029","volume":"106","author":"N Ebert","year":"2024","unstructured":"Ebert, N. et al. Iohexol plasma clearance measurement protocol standardization for adults: a consensus paper of the European Kidney Function Consortium. Kidney Int. 106, 583\u2013596 (2024).","journal-title":"Kidney Int."},{"key":"1031_CR23","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.0000000639","volume":"36","author":"RB Dorshow","year":"2025","unstructured":"Dorshow, R. B., Debreczeny, M. P. & Goldstein, S. L. Glomerular filtration rate measurement utilizing transdermal detection methodology. J. Am. Soc. Nephrol. 36, 1592\u20131602 (2025).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1031_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.kint.2024.06.012","volume":"106","author":"RB Dorshow","year":"2024","unstructured":"Dorshow, R. B., Debreczeny, M. P., Goldstein, S. L. & Shieh, J.-J. Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102). Kidney Int. 106, 679\u2013687 (2024).","journal-title":"Kidney Int."},{"key":"1031_CR25","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard, S. C., McCormick, J., Pui, C.-H., Buddington, R. K. & Harvey, R. D. Preventing and managing toxicities of high-dose methotrexate. Oncologist 21, 1471\u20131482 (2016).","journal-title":"Oncologist"},{"key":"1031_CR26","doi-asserted-by":"publisher","unstructured":"Gupta, S. et al. Effect of intravenous magnesium on cisplatin-associated AKI. J. Am. Soc. Nephrol. https:\/\/doi.org\/10.1681\/ASN.2024f6e9f5yf (2024).","DOI":"10.1681\/ASN.2024f6e9f5yf"},{"key":"1031_CR27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1001\/jamaoncol.2025.0756","volume":"11","author":"S Gupta","year":"2025","unstructured":"Gupta, S. et al. Intravenous magnesium and cisplatin-associated acute kidney injury: a multicenter cohort study. JAMA Oncol. 11, 636\u2013643 (2025).","journal-title":"JAMA Oncol."},{"key":"1031_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2023.151342","volume":"42","author":"S Latcha","year":"2022","unstructured":"Latcha, S. & Shah, C. V. Rescue therapies for AKI in onconephrology: rasburicase and glucarpidase. Semin. Nephrol. 42, 151342 (2022).","journal-title":"Semin. Nephrol."},{"key":"1031_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.ackd.2021.08.001","volume":"28","author":"S Gupta","year":"2021","unstructured":"Gupta, S., Portales-Castillo, I., Daher, A. & Kitchlu, A. Conventional chemotherapy nephrotoxicity. Adv. Chronic Kidney Dis. 28, 402\u2013414.e1 (2021).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"1031_CR30","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.08070715","volume":"11","author":"S Latcha","year":"2016","unstructured":"Latcha, S. et al. Long-term renal outcomes after cisplatin treatment. Clin. J. Am. Soc. Nephrol. 11, 1173\u20131179 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1031_CR31","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1200\/JCO.2017.75.7161","volume":"36","author":"SS Motwani","year":"2018","unstructured":"Motwani, S. S. et al. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J. Clin. Oncol. 36, 682\u2013688 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1031_CR32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/sj.bjc.6600884","volume":"88","author":"FE De Jongh","year":"2003","unstructured":"De Jongh, F. E. et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer 88, 1199\u20131206 (2003).","journal-title":"Br. J. Cancer"},{"key":"1031_CR33","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/ckj\/sfz183","volume":"13","author":"G Ensergueix","year":"2020","unstructured":"Ensergueix, G. et al. Ifosfamide nephrotoxicity in adult patients. Clin. Kidney J. 13, 660\u2013665 (2020).","journal-title":"Clin. Kidney J."},{"key":"1031_CR34","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.ejca.2012.03.009","volume":"48","author":"JK Farry","year":"2012","unstructured":"Farry, J. K., Flombaum, C. D. & Latcha, S. Long term renal toxicity of ifosfamide in adult patients \u2014 5 year data. Eur. J. Cancer 48, 1326\u20131331 (2012).","journal-title":"Eur. J. Cancer"},{"key":"1031_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","volume":"146","author":"N de Rouw","year":"2020","unstructured":"de Rouw, N. et al. Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer 146, 30\u201335 (2020).","journal-title":"Lung Cancer"},{"key":"1031_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s41100-020-00292-x","volume":"6","author":"K Umehara","year":"2020","unstructured":"Umehara, K. et al. Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study. Ren. Replace. Ther. 6, 43 (2020).","journal-title":"Ren. Replace. Ther."},{"key":"1031_CR37","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","volume":"21","author":"H Izzedine","year":"2006","unstructured":"Izzedine, H. et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol. Dial. Transplant. 21, 3038\u20133045 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1031_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/1078155216628324","volume":"23","author":"G Garcia","year":"2017","unstructured":"Garcia, G. & Atallah, J. P. Antineoplastic agents and thrombotic microangiopathy. J. Oncol. Pharm. Pract. 23, 135\u2013142 (2017).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"1031_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/phar.2889","volume":"44","author":"ML Rice","year":"2024","unstructured":"Rice, M. L. et al. Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma. Pharmacotherapy 44, 4\u201312 (2024).","journal-title":"Pharmacotherapy"},{"key":"1031_CR40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0002-9343(99)00041-8","volume":"106","author":"MA Perazella","year":"1999","unstructured":"Perazella, M. A. Crystal-induced acute renal failure. Am. J. Med. 106, 459\u2013465 (1999).","journal-title":"Am. J. Med."},{"key":"1031_CR41","doi-asserted-by":"publisher","first-page":"F369","DOI":"10.1152\/ajprenal.00127.2014","volume":"307","author":"MH Solanki","year":"2014","unstructured":"Solanki, M. H. et al. Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation. Am. J. Physiol. Ren. Physiol. 307, F369\u2013F384 (2014).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1031_CR42","doi-asserted-by":"publisher","first-page":"F35","DOI":"10.1152\/ajprenal.00096.2015","volume":"309","author":"MH Solanki","year":"2015","unstructured":"Solanki, M. H. et al. Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice. Am. J. Physiol. Ren. Physiol. 309, F35\u2013F47 (2015).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1031_CR43","doi-asserted-by":"publisher","first-page":"100351","DOI":"10.1016\/j.esmoop.2021.100351","volume":"7","author":"S Suppadungsuk","year":"2022","unstructured":"Suppadungsuk, S. et al. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study). ESMO Open 7, 100351 (2022).","journal-title":"ESMO Open"},{"key":"1031_CR44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.14740\/jmc4253","volume":"15","author":"L Bertin","year":"2024","unstructured":"Bertin, L. et al. Thrombotic microangiopathy after long-lasting treatment by gemcitabine: description, evolution and treatment of a rare case. J. Med. Cases 15, 272\u2013277 (2024).","journal-title":"J. Med. Cases"},{"key":"1031_CR45","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/jso.27412","volume":"128","author":"S Gupta","year":"2023","unstructured":"Gupta, S. et al. High-dose IV magnesium in mesothelioma patients receiving surgery with hyperthermic intraoperative cisplatin: pilot studies and design of a phase II randomized clinical trial. J. Surg. Oncol. 128, 1141\u20131149 (2023).","journal-title":"J. Surg. Oncol."},{"key":"1031_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2399369319827305","volume":"3","author":"A Kitchlu","year":"2019","unstructured":"Kitchlu, A. & Shirali, A. C. High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: what\u2019s best? J. Onco-Nephrol. 3, 11\u201318 (2019).","journal-title":"J. Onco-Nephrol."},{"key":"1031_CR47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","volume":"23","author":"LB Ramsey","year":"2018","unstructured":"Ramsey, L. B. et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist 23, 52\u201361 (2018).","journal-title":"Oncologist"},{"key":"1031_CR48","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","volume":"14","author":"G Kemp","year":"1996","unstructured":"Kemp, G. et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 14, 2101\u20132112 (1996).","journal-title":"J. Clin. Oncol."},{"key":"1031_CR49","first-page":"72","volume":"26","author":"RL Capizzi","year":"1999","unstructured":"Capizzi, R. L. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects. Semin. Oncol. 26, 72\u201381 (1999).","journal-title":"Semin. Oncol."},{"key":"1031_CR50","first-page":"85","volume":"85","author":"F Castiglione","year":"1999","unstructured":"Castiglione, F., Dalla Mola, A. & Porcile, G. Protection of normal tissues from radiation and cytotoxic therapy: the development of amifostine. Tumori 85, 85\u201391 (1999).","journal-title":"Tumori"},{"key":"1031_CR51","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm, M. et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J. Clin. Oncol. 29, 2514\u20132520 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1031_CR52","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","volume":"23","author":"M Araghi","year":"2023","unstructured":"Araghi, M. et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 23, 162 (2023).","journal-title":"Cancer Cell Int."},{"key":"1031_CR53","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nrneph.2015.15","volume":"11","author":"C Porta","year":"2015","unstructured":"Porta, C., Cosmai, L., Gallieni, M., Pedrazzoli, P. & Malberti, F. Renal effects of targeted anticancer therapies. Nat. Rev. Nephrol. 11, 354\u2013370 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"1031_CR54","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","volume":"50","author":"H Izzedine","year":"2007","unstructured":"Izzedine, H., Rixe, O., Billemont, B., Baumelou, A. & Deray, G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am. J. Kidney Dis. 50, 203\u2013218 (2007).","journal-title":"Am. J. Kidney Dis."},{"key":"1031_CR55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","volume":"46","author":"H Izzedine","year":"2010","unstructured":"Izzedine, H. et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur. J. Cancer 46, 439\u2013448 (2010).","journal-title":"Eur. J. Cancer"},{"key":"1031_CR56","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine, H. et al. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine 93, 333\u2013339 (2014).","journal-title":"Medicine"},{"key":"1031_CR57","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","volume":"30","author":"ES Robinson","year":"2010","unstructured":"Robinson, E. S., Khankin, E. V., Karumanchi, S. A. & Humphreys, B. D. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin. Nephrol. 30, 591\u2013601 (2010).","journal-title":"Semin. Nephrol."},{"key":"1031_CR58","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jamda.2024.02.002","volume":"25","author":"K Makino","year":"2024","unstructured":"Makino, K. et al. Impacts of negative and positive life events on development of social frailty among community-dwelling older adults. J. Am. Med. Dir. Assoc. 25, 690\u2013696.e1 (2024).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"1031_CR59","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/CAD.0b013e3283359c79","volume":"21","author":"AAM Van Der Veldt","year":"2010","unstructured":"Van Der Veldt, A. A. M. et al. Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib. Anticancer. Drugs 21, 439\u2013446 (2010).","journal-title":"Anticancer. Drugs"},{"key":"1031_CR60","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","volume":"12","author":"RM Touyz","year":"2018","unstructured":"Touyz, R. M., Herrmann, S. M. S. & Herrmann, J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J. Am. Soc. Hypertens. 12, 409\u2013425 (2018).","journal-title":"J. Am. Soc. Hypertens."},{"key":"1031_CR61","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann, J. et al. Defining cardiovascular toxicities of cancer therapies: an international cardio-oncology society (IC-OS) consensus statement. Eur. Heart J. 43, 280\u2013299 (2022).","journal-title":"Eur. Heart J."},{"key":"1031_CR62","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1093\/ckj\/sfad195","volume":"16","author":"S Pandey","year":"2023","unstructured":"Pandey, S., Kalaria, A., Jhaveri, K. D., Herrmann, S. M. & Kim, A. S. Management of hypertension in patients with cancer: challenges and considerations. Clin. Kidney J. 16, 2336\u20132348 (2023).","journal-title":"Clin. Kidney J."},{"key":"1031_CR63","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","volume":"80","author":"JB Cohen","year":"2023","unstructured":"Cohen, J. B. et al. Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension 80, e46\u2013e57 (2023).","journal-title":"Hypertension"},{"key":"1031_CR64","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc072330","volume":"358","author":"M Azizi","year":"2008","unstructured":"Azizi, M., Chedid, A. & Oudard, S. Home blood-pressure monitoring in patients receiving sunitinib. N. Engl. J. Med. 358, 95\u201397 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1031_CR65","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11523-009-0106-0","volume":"4","author":"KL Snider","year":"2009","unstructured":"Snider, K. L. & Maitland, M. L. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target. Oncol. 4, 67\u201376 (2009).","journal-title":"Target. Oncol."},{"key":"1031_CR66","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1158\/1078-0432.CCR-09-1717","volume":"15","author":"BD Humphreys","year":"2009","unstructured":"Humphreys, B. D. & Atkins, M. B. Rapid development of hypertension by sorafenib: toxicity or target? Clin. Cancer Res. 15, 5947\u20135949 (2009).","journal-title":"Clin. Cancer Res."},{"key":"1031_CR67","doi-asserted-by":"crossref","unstructured":"McFarlane, S. I. & Bakris, G. L. Diabetes and Hypertension: Evaluation and Management. Diabetes and Hypertension: Evaluation and Management 1st edn (Humana Press, 2012).","DOI":"10.1007\/978-1-60327-357-2"},{"key":"1031_CR68","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams, B. et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021\u20133104 (2018).","journal-title":"Eur. Heart J."},{"key":"1031_CR69","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028050","volume":"12","author":"DCH Van Dorst","year":"2023","unstructured":"Van Dorst, D. C. H. et al. Treatment and implications of vascular endothelial growth factor inhibitor-induced blood pressure rise: a clinical cohort study. J. Am. Heart Assoc. 12, e028050 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"1031_CR70","doi-asserted-by":"publisher","first-page":"1043874","DOI":"10.3389\/fneph.2023.1043874","volume":"3","author":"R Fenoglio","year":"2023","unstructured":"Fenoglio, R. et al. The need for kidney biopsy in the management of side effects of target and immunotherapy. Front. Nephrol. 3, 1043874 (2023).","journal-title":"Front. Nephrol."},{"key":"1031_CR71","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.940906","volume":"24","author":"WSC Padilha","year":"2023","unstructured":"Padilha, W. S. C. et al. Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: a case report. Am. J. Case Rep. 24, e940906 (2023).","journal-title":"Am. J. Case Rep."},{"key":"1031_CR72","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar, F. B. et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 90, 638\u2013647 (2016).","journal-title":"Kidney Int."},{"key":"1031_CR73","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ndt\/gfy105","volume":"34","author":"S Manohar","year":"2019","unstructured":"Manohar, S. et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol. Dialysis Transplant. 34, 108\u2013117 (2019).","journal-title":"Nephrol. Dialysis Transplant."},{"key":"1031_CR74","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejim.2023.05.034","volume":"115","author":"W Xie","year":"2023","unstructured":"Xie, W. et al. Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: systematic review and meta-analysis of real-world evidence. Eur. J. Intern. Med. 115, 88\u201395 (2023).","journal-title":"Eur. J. Intern. Med."},{"key":"1031_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252978","volume":"16","author":"MS Koks","year":"2021","unstructured":"Koks, M. S. et al. Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study. PLoS One 16, e0252978 (2021).","journal-title":"PLoS One"},{"key":"1031_CR76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000467","volume":"8","author":"A Meraz-Mu\u00f1oz","year":"2020","unstructured":"Meraz-Mu\u00f1oz, A. et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J. Immunother. Cancer 8, e000467 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1031_CR77","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","volume":"14","author":"H Seethapathy","year":"2019","unstructured":"Seethapathy, H. et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin. J. Am. Soc. Nephrol. 14, 1692\u20131700 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1031_CR78","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1159\/000538274","volume":"55","author":"A Mohan","year":"2024","unstructured":"Mohan, A. et al. Association of proton pump inhibitor use and immune checkpoint inhibitor-mediated acute kidney injury: a meta-analysis and a review of related outcomes. Am. J. Nephrol. 55, 439\u2013449 (2024).","journal-title":"Am. J. Nephrol."},{"key":"1031_CR79","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar, F. B. et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J. Am. Soc. Nephrol. 31, 435\u2013446 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1031_CR80","doi-asserted-by":"publisher","first-page":"sfad292","DOI":"10.1093\/ckj\/sfad292","volume":"17","author":"JJ Chen","year":"2024","unstructured":"Chen, J. J. et al. All-cause and immune checkpoint inhibitor\u2013associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality. Clin. Kidney J. 17, sfad292 (2024).","journal-title":"Clin. Kidney J."},{"key":"1031_CR81","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","volume":"7","author":"O Mamlouk","year":"2019","unstructured":"Mamlouk, O. et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J. Immunother. Cancer 7, 2 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1031_CR82","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.xkme.2020.05.015","volume":"2","author":"SM Herrmann","year":"2020","unstructured":"Herrmann, S. M., Alexander, M. P., Romero, M. F. & Zand, L. Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor \u2014 a report of 3 cases. Kidney Med. 2, 657\u2013662 (2020).","journal-title":"Kidney Med."},{"key":"1031_CR83","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2215\/CJN.14671121","volume":"17","author":"NN Uppal","year":"2022","unstructured":"Uppal, N. N., Workeneh, B. T., Rondon-Berrios, H. & Jhaveri, K. D. Electrolyte and acid-base disorders associated with cancer immunotherapy. Clin. J. Am. Soc. Nephrol. 17, 922\u2013933 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1031_CR84","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","volume":"6","author":"A Kitchlu","year":"2021","unstructured":"Kitchlu, A. et al. A systematic review of immune checkpoint inhibitor\u2013associated glomerular disease. Kidney Int. Rep. 6, 66\u201377 (2021).","journal-title":"Kidney Int. Rep."},{"key":"1031_CR85","doi-asserted-by":"publisher","first-page":"112967","DOI":"10.1016\/j.ejca.2023.112967","volume":"191","author":"N Lumlertgul","year":"2023","unstructured":"Lumlertgul, N. et al. Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study. Eur. J. Cancer 191, 112967 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1031_CR86","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","volume":"41","author":"T Won","year":"2022","unstructured":"Won, T. et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 41, 111611 (2022).","journal-title":"Cell Rep."},{"key":"1031_CR87","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","volume":"611","author":"ML Axelrod","year":"2022","unstructured":"Axelrod, M. L. et al. T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis. Nature 611, 818\u2013826 (2022).","journal-title":"Nature"},{"key":"1031_CR88","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.ekir.2022.11.020","volume":"8","author":"N Farooqui","year":"2023","unstructured":"Farooqui, N. et al. Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. Rep. 8, 628\u2013641 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1031_CR89","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41423-024-01197-z","volume":"21","author":"F Arnold","year":"2024","unstructured":"Arnold, F. et al. Tissue-resident memory T cells break tolerance to renal autoantigens and orchestrate immune-mediated nephritis. Cell Mol. Immunol. 21, 1066\u20131081 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"1031_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37230-4","volume":"14","author":"GS Dunlap","year":"2023","unstructured":"Dunlap, G. S. et al. Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy. Nat. Commun. 14, 1549 (2023).","journal-title":"Nat. Commun."},{"key":"1031_CR91","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655\u2013671.e22 (2020).","journal-title":"Cell"},{"key":"1031_CR92","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","volume":"149","author":"P Ma","year":"2024","unstructured":"Ma, P. et al. Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. Circulation 149, 48\u201366 (2024).","journal-title":"Circulation"},{"key":"1031_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08105-5","author":"SM Blum","year":"2024","unstructured":"Blum, S. M. et al. Immune responses in checkpoint myocarditis across heart, blood and tumour. Nature https:\/\/doi.org\/10.1038\/s41586-024-08105-5 (2024).","journal-title":"Nature"},{"key":"1031_CR94","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165108","author":"S Singh","year":"2022","unstructured":"Singh, S. et al. Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.165108 (2022).","journal-title":"JCI Insight"},{"key":"1031_CR95","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.2215\/CJN.00920121","volume":"16","author":"BA Adam","year":"2021","unstructured":"Adam, B. A. et al. Gene expression profiling in kidney transplants with immune checkpoint inhibitor\u2013associated adverse events. Clin. J. Am. Soc. Nephrol. 16, 1376\u20131386 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1031_CR96","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.ekir.2024.02.1396","volume":"9","author":"IH Hanif","year":"2024","unstructured":"Hanif, I. H. et al. Immune checkpoint therapy-induced lupus nephritis. Kidney Int. Rep. 9, 1534\u20131537 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1031_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002500","volume":"8","author":"F Aqeel","year":"2022","unstructured":"Aqeel, F., Monroy-Trujillo, J. & Geetha, D. Immune checkpoint inhibitors as potential triggers for ANCA vasculitis. RMD Open 8, e002500 (2022).","journal-title":"RMD Open"},{"key":"1031_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.01.021","author":"SC Asby","year":"2025","unstructured":"Asby, S. C. et al. Pathological findings of immunotherapy-induced nephrotoxicity in a humanized immune system mouse model. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2025.01.021 (2025).","journal-title":"Kidney Int."},{"key":"1031_CR99","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","volume":"6","author":"B Isik","year":"2021","unstructured":"Isik, B. et al. Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events. Kidney Int. Rep. 6, 1022\u20131031 (2021).","journal-title":"Kidney Int. Rep."},{"key":"1031_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006222","volume":"11","author":"ME Sise","year":"2023","unstructured":"Sise, M. E. et al. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis. J. Immunother. Cancer 11, e006222 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1031_CR101","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae257","author":"E-B Barbir","year":"2024","unstructured":"Barbir, E.-B. et al. Biomarker guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis. Nephrol. Dial. Transpl. https:\/\/doi.org\/10.1093\/ndt\/gfae257 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1031_CR102","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168950","volume":"133","author":"DG Moledina","year":"2023","unstructured":"Moledina, D. G. et al. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. J. Clin. Investig. 133, e168950 (2023).","journal-title":"J. Clin. Investig."},{"key":"1031_CR103","doi-asserted-by":"publisher","DOI":"10.1172\/JCI182275","volume":"134","author":"S Gupta","year":"2024","unstructured":"Gupta, S. et al. F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury. J. Clin. Invest. 134, e182275 (2024).","journal-title":"J. Clin. Invest."},{"key":"1031_CR104","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.kint.2018.11.009","volume":"96","author":"S Manohar","year":"2019","unstructured":"Manohar, S. & Albright, R. C. Interstitial nephritis in immune checkpoint inhibitor therapy. Kidney Int. 96, 252 (2019).","journal-title":"Kidney Int."},{"key":"1031_CR105","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","volume":"7","author":"D Qualls","year":"2019","unstructured":"Qualls, D. et al. Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis. J. Immunother. Cancer 7, 356 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1031_CR106","doi-asserted-by":"publisher","first-page":"sfae200","DOI":"10.1093\/ckj\/sfae200","volume":"17","author":"F Gomez-Preciado","year":"2024","unstructured":"Gomez-Preciado, F. et al. Urinary soluble PD-1 as a biomarker of checkpoint inhibitor-induced acute tubulointerstitial nephritis. Clin. Kidney J. 17, sfae200 (2024).","journal-title":"Clin. Kidney J."},{"key":"1031_CR107","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1031_CR108","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.kint.2024.09.017","volume":"107","author":"SM Herrmann","year":"2025","unstructured":"Herrmann, S. M. et al. Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology. Kidney Int. 107, 21\u201332 (2025).","journal-title":"Kidney Int."},{"key":"1031_CR109","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson, J. A. et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J. Natl Compr. Cancer Netw. 18, 230\u2013241 (2020).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"1031_CR110","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002292","volume":"9","author":"MD Lee","year":"2021","unstructured":"Lee, M. D. et al. Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. J. Immunother. Cancer 9, e002292 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1031_CR111","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005646","volume":"10","author":"S Gupta","year":"2022","unstructured":"Gupta, S. et al. Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI. J. Immunother. Cancer 10, e005646 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1031_CR112","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000511256","volume":"46","author":"R Fenoglio","year":"2021","unstructured":"Fenoglio, R. et al. The challenging management of cancer: an immunonephrologist\u2019s perspective. Kidney Blood Press. Res. 46, 114\u2013120 (2021).","journal-title":"Kidney Blood Press. Res."},{"key":"1031_CR113","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41581-022-00630-8","volume":"18","author":"B Sprangers","year":"2022","unstructured":"Sprangers, B., Leaf, D. E., Porta, C., Soler, M. J. & Perazella, M. A. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nat. Rev. Nephrol. 18, 794\u2013805 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1031_CR114","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","volume":"100","author":"N Murakami","year":"2021","unstructured":"Murakami, N. et al. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 100, 196\u2013205 (2021).","journal-title":"Kidney Int."},{"key":"1031_CR115","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejca.2021.01.038","volume":"148","author":"LS Nguyen","year":"2021","unstructured":"Nguyen, L. S. et al. Transplant rejections associated with immune checkpoint inhibitors: a pharmacovigilance study and systematic literature review. Eur. J. Cancer 148, 36\u201347 (2021).","journal-title":"Eur. J. Cancer"},{"key":"1031_CR116","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.rdc.2024.01.001","volume":"50","author":"JA Sparks","year":"2024","unstructured":"Sparks, J. A. Pre-existing autoimmune diseases and immune checkpoint inhibitors for cancer treatment: considerations about initiation, flares, immune-related adverse events, and cancer progression. Rheum. Dis. Clin. North Am. 50, 147\u2013159 (2024).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"1031_CR117","first-page":"917.e1","volume":"30","author":"R Cusatis","year":"2024","unstructured":"Cusatis, R. et al. Current trends and outcomes in cellular therapy activity in the United States, including prospective patient-reported outcomes data collection in the Center for International Blood and Marrow Transplant Research Registry. Transpl. Cell Ther. 30, 917.e1\u2013917.e12 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"1031_CR118","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.bbmt.2019.12.766","volume":"26","author":"J Hsu","year":"2020","unstructured":"Hsu, J. et al. Outcomes of allogeneic stem cell transplant for elderly patients with hematologic malignancies. Biol. Blood Marrow Transplant. 26, 789\u2013797 (2020).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"1031_CR119","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMra1404711","volume":"374","author":"S Hingorani","year":"2016","unstructured":"Hingorani, S. Renal complications of hematopoietic-cell transplantation. N. Engl. J. Med. 374, 2256\u20132267 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1031_CR120","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.bbmt.2015.12.014","volume":"22","author":"O Beyar-Katz","year":"2016","unstructured":"Beyar-Katz, O. et al. Adult nephrotic syndrome after hematopoietic stem cell transplantation: renal pathology is the best predictor of response to therapy. Biol. Blood Marrow Transplant. 22, 975\u2013981 (2016).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"1031_CR121","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","volume":"76","author":"S Gupta","year":"2020","unstructured":"Gupta, S. et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma. Am. J. Kidney Dis. 76, 63\u201371 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"1031_CR122","doi-asserted-by":"publisher","first-page":"1125357","DOI":"10.3389\/fimmu.2023.1125357","volume":"14","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed\/refractory multiple myeloma. Front. Immunol. 14, 1125357 (2023).","journal-title":"Front. Immunol."},{"key":"1031_CR123","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1158\/2767-9764.CRC-24-0250","volume":"4","author":"JP Tang","year":"2024","unstructured":"Tang, J. P. et al. Hypophosphatemia correction reduces ICANS incidence and duration in CAR T-cell therapy: a pooled clinical trial analysis. Cancer Res. Commun. 4, 2589\u20132597 (2024).","journal-title":"Cancer Res. Commun."},{"key":"1031_CR124","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.bbmt.2008.09.015","volume":"14","author":"SR Hingorani","year":"2008","unstructured":"Hingorani, S. R. et al. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol. Blood Marrow Transplant. 14, 1365\u20131372 (2008).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"1031_CR125","first-page":"151","volume":"29","author":"ML Schoettler","year":"2023","unstructured":"Schoettler, M. L. et al. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant. Res. Transpl. Cell Ther. 29, 151\u2013163 (2023).","journal-title":"Res. Transpl. Cell Ther."},{"key":"1031_CR126","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1182\/hematology.2020006913","volume":"2020","author":"G Palladini","year":"2020","unstructured":"Palladini, G., Milani, P. & Merlini, G. Management of AL amyloidosis in 2020. Hematology Am. Soc. Hematol. Educ. Program 2020, 363\u2013371 (2020).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"1031_CR127","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"1031_CR128","doi-asserted-by":"publisher","first-page":"100674","DOI":"10.1016\/j.xkme.2023.100674","volume":"5","author":"G Roy","year":"2023","unstructured":"Roy, G. et al. Kidney biopsy findings among allogenic hematopoietic stem cell transplant recipients with kidney injury: a case series. Kidney Med. 5, 100674 (2023).","journal-title":"Kidney Med."},{"key":"1031_CR129","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bbmt.2017.11.008","volume":"24","author":"M Girsberger","year":"2018","unstructured":"Girsberger, M., Halter, J. P., Hopfer, H., Dickenmann, M. & Menter, T. Kidney pathology after hematologic cell transplantation \u2014 a single-center observation study of indication biopsies and autopsies. Biol. Blood Marrow Transplant. 24, 571\u2013580 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"1031_CR130","doi-asserted-by":"publisher","DOI":"10.1159\/000529699","author":"EE John","year":"2023","unstructured":"John, E. E. et al. Patterns of renal dysfunction and profile of kidney biopsies in hematopoietic stem cell transplant recipients. Glomerular Dis. https:\/\/doi.org\/10.1159\/000529699 (2023).","journal-title":"Glomerular Dis."},{"key":"1031_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.779881","volume":"12","author":"M Miyata","year":"2022","unstructured":"Miyata, M. et al. Recent advances of acute kidney injury in hematopoietic cell transplantation. Front. Immunol. 12, 779881 (2022).","journal-title":"Front. Immunol."},{"key":"1031_CR132","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.2215\/CJN.19801220","volume":"16","author":"MH Abramson","year":"2021","unstructured":"Abramson, M. H. et al. Acute kidney injury in the modern era of allogeneic hematopoietic stem cell transplantation. Clin. J. Am. Soc. Nephrol. 16, 1318\u20131327 (2021).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1031_CR133","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/s41409-022-01744-0","volume":"57","author":"K Madsen","year":"2022","unstructured":"Madsen, K. et al. Acute kidney injury within 100 days post allogeneic hematopoietic cell transplantation is associated with increased risk of post-transplant complications and poor transplant outcomes. Bone Marrow Transpl. 57, 1411\u20131420 (2022).","journal-title":"Bone Marrow Transpl."},{"key":"1031_CR134","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/bmt.2017.22","volume":"52","author":"A Saad","year":"2017","unstructured":"Saad, A. & Lamb, L. S. Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future. Bone Marrow Transplant. 52, 1241\u20131248 (2017).","journal-title":"Bone Marrow Transplant."},{"key":"1031_CR135","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41409-019-0705-z","volume":"55","author":"M Mohty","year":"2020","unstructured":"Mohty, M. et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transpl. 55, 485\u2013495 (2020).","journal-title":"Bone Marrow Transpl."},{"key":"1031_CR136","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty, M. et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives \u2014 a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 50, 781\u2013789 (2015).","journal-title":"Bone Marrow Transplant."},{"key":"1031_CR137","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"SC Howard","year":"2011","unstructured":"Howard, S. C., Jones, D. P. & Pui, C.-H. The tumor lysis syndrome. N. Engl. J. Med. 364, 1844\u20131854 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1031_CR138","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321\u20133330 (2016).","journal-title":"Blood"},{"key":"1031_CR139","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/bjh.16457","volume":"189","author":"N Epperla","year":"2020","unstructured":"Epperla, N. et al. Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy. Br. J. Haematol. 189, 1171\u20131181 (2020).","journal-title":"Br. J. Haematol."},{"key":"1031_CR140","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2165\/00003495-200969020-00004","volume":"69","author":"CM Choi","year":"2009","unstructured":"Choi, C. M., Schmaier, A. H., Snell, M. R. & Lazarus, H. M. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs 69, 183\u2013198 (2009).","journal-title":"Drugs"},{"key":"1031_CR141","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/hematology.2024000545","volume":"2024","author":"A Li","year":"2024","unstructured":"Li, A. & Sartain, S. E. Transplant-associated TMA: the conundrum of diagnosis and treatment. Hematol. Am. Soc. Hematol. Educ. Program 2024, 206\u2013213 (2024).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"1031_CR142","doi-asserted-by":"publisher","first-page":"1064203","DOI":"10.3389\/fimmu.2022.1064203","volume":"13","author":"ML Schoettler","year":"2022","unstructured":"Schoettler, M. L., Bhatt, H. & Vasu, S. A systematic review of diagnostic, prognostic, and risk blood and urine biomarkers of transplant-associated thrombotic microangiopathy. Front. Immunol. 13, 1064203 (2022).","journal-title":"Front. Immunol."},{"issue":"Suppl. 4","key":"1031_CR143","first-page":"S57","volume":"98","author":"S Jodele","year":"2023","unstructured":"Jodele, S. & Sabulski, A. Reeling in complement in transplant-associated thrombotic microangiopathy: you\u2019re going to need a bigger boat. Am. J. Hematol. 98 (Suppl. 4), S57\u2013S73 (2023).","journal-title":"Am. J. Hematol."},{"key":"1031_CR144","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1053\/j.ackd.2021.09.002","volume":"29","author":"N Murakami","year":"2022","unstructured":"Murakami, N., Webber, A. B. & Nair, V. Transplant onconephrology in patients with kidney transplants. Adv. Chronic Kidney Dis. 29, 188\u2013200.e1 (2022).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"1031_CR145","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.bbmt.2019.08.021","volume":"26","author":"A Shinohara","year":"2020","unstructured":"Shinohara, A. et al. Hematopoietic stem cell transplantation in solid organ recipients with emphasis on transplant complications: a nationwide retrospective survey on behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group. Biol. Blood Marrow Transplant. 26, 66\u201375 (2020).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"1031_CR146","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/ajt.13017","volume":"15","author":"GW Basak","year":"2015","unstructured":"Basak, G. W. et al. Allogeneic hematopoietic stem cell transplantation in solid organ transplant recipients: a retrospective, multicenter study of the EBMT. Am. J. Transplant. 15, 705\u2013714 (2015).","journal-title":"Am. J. Transplant."},{"key":"1031_CR147","volume":"69","author":"R Hernani","year":"2021","unstructured":"Hernani, R. et al. CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. Curr. Res. Transl. Med. 69, 103304 (2021).","journal-title":"Curr. Res. Transl. Med."},{"key":"1031_CR148","first-page":"73.e1","volume":"30","author":"S Yamshon","year":"2024","unstructured":"Yamshon, S. et al. Efficacy and toxicity of CD19 chimeric antigen receptor T cell therapy for lymphoma in solid organ transplant recipients: a systematic review and meta-analysis. Transpl. Cell Ther. 30, 73.e1\u201373.e12 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"1031_CR149","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41409-022-01907-z","volume":"58","author":"AJ Portuguese","year":"2023","unstructured":"Portuguese, A. J. et al. CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review. Bone Marrow Transplant. 58, 353\u2013359 (2023).","journal-title":"Bone Marrow Transplant."},{"key":"1031_CR150","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/ajt.16367","volume":"21","author":"S Krishnamoorthy","year":"2021","unstructured":"Krishnamoorthy, S. et al. CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. Am. J. Transpl. 21, 809\u2013814 (2021).","journal-title":"Am. J. Transpl."},{"key":"1031_CR151","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/s41409-020-01145-1","volume":"56","author":"E Luttwak","year":"2021","unstructured":"Luttwak, E. et al. Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease \u2014 a single center case series. Bone Marrow Transpl. 56, 1031\u20131037 (2021).","journal-title":"Bone Marrow Transpl."},{"key":"1031_CR152","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1182\/blood.2020008759","volume":"137","author":"O Mamlouk","year":"2021","unstructured":"Mamlouk, O. et al. Safety of CAR T-cell therapy in kidney transplant recipients. Blood 137, 2558\u20132562 (2021).","journal-title":"Blood"},{"key":"1031_CR153","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.semnephrol.2022.01.003","volume":"42","author":"B Schreiber","year":"2022","unstructured":"Schreiber, B., Abdelrahim, M., Abudayyeh, A. & Murakami, N. Emerging Concepts in managing malignancy in kidney transplant patients. Semin. Nephrol. 42, 63\u201375 (2022).","journal-title":"Semin. Nephrol."},{"key":"1031_CR154","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000486359","volume":"139","author":"F Martini","year":"2018","unstructured":"Martini, F. et al. Plasma cell disorders and dialysis-dependent renal failure: safety and efficacy of autologous stem cell transplantation. Acta Haematol. 139, 101\u2013103 (2018).","journal-title":"Acta Haematol."},{"key":"1031_CR155","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.clml.2015.03.003","volume":"15","author":"R El Fakih","year":"2015","unstructured":"El Fakih, R. et al. Autologous hematopoietic stem cell transplantation in dialysis-dependent myeloma patients. Clin. Lymphoma Myeloma Leuk. 15, 472\u2013476 (2015).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1031_CR156","doi-asserted-by":"publisher","unstructured":"Shadman, M., Sandmaier, B. M., Maloney, D. G., Pagel, J. M. & Hingorani, S. Nonmyeloablative allogeneic hematopoietic stem cell transplant in patients with end stage renal disease requiring dialysis \u2013 a single institution experience. Biol. Blood Marrow Transplant. https:\/\/doi.org\/10.1016\/j.bbmt.2013.12.422 (2014).","DOI":"10.1016\/j.bbmt.2013.12.422"},{"key":"1031_CR157","doi-asserted-by":"publisher","first-page":"100856","DOI":"10.1016\/j.xkme.2024.100856","volume":"6","author":"WLW Pak","year":"2024","unstructured":"Pak, W. L. W. et al. Chimeric antigen receptor (CAR) T-cell therapy use in patients with multiple myeloma and kidney failure on maintenance hemodialysis: a report of 2 cases. Kidney Med. 6, 100856 (2024).","journal-title":"Kidney Med."},{"key":"1031_CR158","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.33387","volume":"7","author":"AB Karol","year":"2024","unstructured":"Karol, A. B. et al. Heterogeneity in methods of estimating kidney function for cancer clinical trial eligibility. JAMA Netw. Open 7, e2433387 (2024).","journal-title":"JAMA Netw. Open"},{"key":"1031_CR159","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jnci\/djy167","volume":"111","author":"A Kitchlu","year":"2019","unstructured":"Kitchlu, A. et al. Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study. J. Natl Cancer Inst. 111, 727\u2013736 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"1031_CR160","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/bjc.2014.503","volume":"111","author":"AB Suttle","year":"2014","unstructured":"Suttle, A. B. et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br. J. Cancer 111, 1909\u20131916 (2014).","journal-title":"Br. J. Cancer"},{"key":"1031_CR161","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1158\/1078-0432.CCR-16-1255","volume":"22","author":"RB Verheijen","year":"2016","unstructured":"Verheijen, R. B. et al. Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clin. Cancer Res. 22, 5738\u20135746 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1031_CR162","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/cpt.757","volume":"102","author":"JO Miners","year":"2017","unstructured":"Miners, J. O., Yang, X., Knights, K. M. & Zhang, L. The role of the kidney in drug elimination: transport, metabolism, and the impact of kidney disease on drug clearance. Clin. Pharmacol. Ther. 102, 436\u2013449 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1031_CR163","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1093\/annonc\/mdp598","volume":"21","author":"N Janus","year":"2010","unstructured":"Janus, N., Thariat, J., Boulanger, H., Deray, G. & Launay-Vacher, V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann. Oncol. 21, 1395\u20131403 (2010).","journal-title":"Ann. Oncol."},{"key":"1031_CR164","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/clpt.2008.59","volume":"83","author":"T Nolin","year":"2008","unstructured":"Nolin, T., Naud, J., Leblond, F. & Pichette, V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin. Pharmacol. Ther. 83, 898\u2013903 (2008).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1031_CR165","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000736","author":"E Costa","year":"2025","unstructured":"Costa, E. et al. Update on the assessment of glomerular filtration rate in patients with cancer. Kidney360 https:\/\/doi.org\/10.34067\/KID.0000000736 (2025).","journal-title":"Kidney360"},{"key":"1031_CR166","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1093\/ndt\/gfae089","volume":"39","author":"R Bellomo","year":"2024","unstructured":"Bellomo, R. et al. Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup. Nephrol. Dial. Transpl. 39, 1945\u20131964 (2024).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1031_CR167","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2215\/CJN.05630614","volume":"10","author":"TD Nolin","year":"2015","unstructured":"Nolin, T. D. et al. Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the kidney health initiative. Clin. J. Am. Soc. Nephrol. 10, 159\u2013164 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1031_CR168","doi-asserted-by":"publisher","first-page":"1436896","DOI":"10.3389\/fneph.2024.1436896","volume":"4","author":"RM Lyrio","year":"2024","unstructured":"Lyrio, R. M. et al. Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches. Front. Nephrol. 4, 1436896 (2024).","journal-title":"Front. Nephrol."},{"key":"1031_CR169","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-024-04303-2","author":"F Shahrahmani","year":"2024","unstructured":"Shahrahmani, F. et al. Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management. Int. Urol. Nephrol. https:\/\/doi.org\/10.1007\/s11255-024-04303-2 (2024).","journal-title":"Int. Urol. Nephrol."},{"key":"1031_CR170","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.47739\/pharmacology1184","volume":"12","author":"LE Thompson","year":"2024","unstructured":"Thompson, L. E. et al. A pharmacokinetic\/toxicodynamic model of cisplatin nephrotoxicity using the kidney injury molecule-1 biomarker. J. Pharmacol. Clin. Toxicol. 12, 1184 (2024).","journal-title":"J. Pharmacol. Clin. Toxicol."},{"key":"1031_CR171","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s10147-023-02377-z","volume":"28","author":"H Nishiyama","year":"2023","unstructured":"Nishiyama, H. et al. Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int. J. Clin. Oncol. 28, 1298\u20131314 (2023).","journal-title":"Int. J. Clin. Oncol."},{"key":"1031_CR172","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/jca.20302","volume":"26","author":"DM Ward","year":"2011","unstructured":"Ward, D. M. Conventional apheresis therapies: a review. J. Clin. Apher. 26, 230\u2013238 (2011).","journal-title":"J. Clin. Apher."},{"key":"1031_CR173","first-page":"308.e1","volume":"27","author":"A Li","year":"2021","unstructured":"Li, A. et al. Prognostic biomarkers for thrombotic microangiopathy after acute graft-versus-host disease: a nested case-control study. Transpl. Cell Ther. 27, 308.e1\u2013308.e8 (2021).","journal-title":"Transpl. Cell Ther."},{"key":"1031_CR174","doi-asserted-by":"publisher","first-page":"107602961989268","DOI":"10.1177\/1076029619892684","volume":"26","author":"Z Xu","year":"2020","unstructured":"Xu, Z. et al. von Willebrand factor as a predictor for transplant-associated thrombotic microangiopathy. Clin. Appl. Thromb. Hemost. 26, 1076029619892684 (2020).","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"1031_CR175","doi-asserted-by":"publisher","first-page":"695037","DOI":"10.3389\/fimmu.2021.695037","volume":"12","author":"H Okamura","year":"2021","unstructured":"Okamura, H. et al. Early elevation of complement factor Ba is a predictive biomarker for transplant-associated thrombotic microangiopathy. Front. Immunol. 12, 695037 (2021).","journal-title":"Front. Immunol."},{"key":"1031_CR176","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.3390\/ijms24086960","volume":"24","author":"D Vythoulkas","year":"2023","unstructured":"Vythoulkas, D. et al. Endothelial injury syndromes after allogeneic hematopoietic stem cell transplantation: angiopetin-2 as a novel predictor of the outcome and the role of functional autoantibodies against angiotensin II type 1 and endothelin A receptor. Int. J. Mol. Sci. 24, 6960 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1031_CR177","first-page":"S89","volume":"31","author":"A Scheck","year":"2025","unstructured":"Scheck, A. et al. Large language models to optimize data abstraction for CIBMTR reporting: a pilot study. Transpl. Cell Ther. 31, S89 (2025).","journal-title":"Transpl. Cell Ther."},{"key":"1031_CR178","doi-asserted-by":"publisher","first-page":"7489","DOI":"10.1182\/blood-2024-207380","volume":"144","author":"J Wang","year":"2024","unstructured":"Wang, J. & Nazha, A. Autonomous analysis of CIBMTR datasets using artificial intelligence agents. Blood 144, 7489\u20137489 (2024).","journal-title":"Blood"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01031-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01031-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01031-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T13:01:55Z","timestamp":1774270915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-01031-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":178,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1038\/s41581-025-01031-3","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"24 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The ADQI consensus meeting was sponsored by Alexion, Baxter, Bioporto, BTG\/SERB Pharmaceuticals, Calliditas, Medibeacon, Merck, Nova Biomedical, Novartis, Pfizer and SeaStar Medical. Sponsoring entities had no input in the discussions or in the final consensus statements or manuscript preparation. K.B. receives research support to her institution from StemLine Therapeutics. L.C. serves on the advisory boards of SERB and on speaker panels for SERB and Pfizer. She also serves as Editor-in-Chief of the\n                      Journal of Onco-Nephrology\n                      . R.F. had teaching honoraria from Vifor. M.F. serves on the advisory boards of GlaxoSmithKline and on speaker panels for Fresenius Medical Care, Jafron, B. Braun, Nipro and GlaxoSmithKline. He also serves on the editorial board for\n                      Kidney and Blood Pressure Research\n                      . L.G.F. reports research support from Baxter, Medibeacon, OrthoDiagnostics, SphingoTec and the NIHR. He has been on speaker panels for Fresenius Medical Care, Cytosorbents, SphingoTec and Vantive. I.G.G. reports an advisory board fee from T-knife Therapeutics, Inc. and support from NIH MSK Core Grant P30CA008748. S.L.G. receives consulting income from SeaStar Medical, BioPorto Diagnostics, Calcimedica, Mozarc Medical, Otsuka, Baxter Healthcare, Renibus Therapeutics and Novartis. He serves as a paid member of the Data Safety Monitoring Board for Silver Creek Therapeutics and Novartis. He serves on Speaker\u2019s Panels for Baxter Healthcare and Fresenius Medical Care. He has stock options from MediBeacon, Inc. and serves as their Director of Clinical Development. He and his employer receive licensing royalties from RAIDAR Health. S.G. reports research support from the NIH, NIDDK K23DK125672 and R03DK141708. She also reports research funding from BTG International, Janssen, GE Healthcare and AstraZeneca, outside the submitted work. She is a consultant for Alexion, Mersana, MediBeacon and Orion Pharma. She founded and is Co-President Emeritus of the American Society of Onconephrology (unpaid). She also received speaker fees from Springer Inc. S.M.H. reports research support from Mayo Clinic Center for Clinical and Translational Science grant number UL1TR002377 and the Fulk Career Development Award. She serves as Review Section Editor for onconephrology for\n                      Nephrology Dialysis Transplantation\n                      . E.A.J. is supported by NIH grants R01DK129299 and P30CA008748. K.D.J. reports consultancy agreements with Novartis, Otsuka, Calliditas, George Clinicals, Vera Therapeutics and Travere Therapeutics; reports honoraria from the American Society of Nephrology and the International Society of Nephrology; is a paid contributor to\n                      UpToDate\n                      and is Section Editor for onconephrology for\n                      Nephrology Dialysis Transplantation\n                      ; serves on the editorial boards of\n                      American Journal of Kidney Diseases\n                      ,\n                      CJASN\n                      ,\n                      Clinical Kidney Journal\n                      ,\n                      Frontiers in Nephrology\n                      ,\n                      Journal of Onco-Nephrology\n                      and\n                      Kidney International\n                      ; and serves as the Editor-in-Chief of\n                      ASN Kidney News\n                      . S.K. reports consultancy agreement with George Clinicals, serves on the editorial boards of\n                      Advances in Kidney Disease and Health\n                      and\n                      N\u00e9phrologie et Th\u00e9rapeutique\n                      , as a Review Editor for\n                      Frontiers in Nephrology\n                      and as a board member for the American Society of Onconephrology. A.K. administers funding from Amgen and Janssen for the University Health Network Onco-Nephrology Fellowship and serves as the President of the American Society of Onconephrology. H.J.L. receives research funding from Alexion (AstraZeneca), Nexcella, Janssen, Abbvie, Prothena and Protego. She has served in consultant\/advisory roles to Alexion (AstraZeneca), Nexcella, Karyopharm, Arcellx, Abbvie and Pfizer. D.E.L. is supported by NIH grants R01DK125786, R01DK126685 and U01AG089040, has received research support from BioPorto, BTG International, Metro International Biotech LLC, Renibus Therapeutics, Inc. and Alexion Pharmaceuticals, has served as a consultant for Sidereal Therapeutics, MexBrain, Entrada Therapeutics, CardioRenal Systems, Inc. and Alexion Pharmaceuticals, and served as a Co-Chair of a Safety Monitoring Committee for EMD Serono Research and Development Institute, Inc. P.L. is an Associate Editor for\n                      Cardiorenal Medicine\n                      ,\n                      Blood Purification\n                      and\n                      Frontiers in Nephrology\n                      and serves on the editorial board for the AKI section of the\n                      Journal of Nephrology\n                      . He has participated in speaker panels or advisory boards sponsored by AstraZeneca, Bayer, Jafron and GSK. J.M. is an editorial board member of\n                      Nephrology Dialysis Transplantation\n                      (Transplantation section). G.M. serves on the editorial boards of\n                      Kidney International\n                      ,\n                      Kidney International Reports\n                      and the\n                      Journal of Onco-Nephrology\n                      . N.M. reports research support from NIH, R01DK137980; is a consultant for Otsuka, Asahi Kasei, Akebia and Sanofi; received honorarium from Elsevier; serves on the editorial board of\n                      Transplantation\n                      . M.O. received research funding from bioM\u00e9rieux and Baxter, which was paid to the institution. A.P. has served on the advisory boards of GlaxoSmithKline, Otsuka, Astellas, and Teva Pharma and participated in speaker panels for Amgen, Menarini, AstraZeneca, Bayer, Alexion and Boehringer Lilly. Additionally, he serves on the editorial board for the\n                      Journal of Onco-Nephrology\n                      . M.A.P. serves as co-Editor-in-Chief of the\n                      Journal of Onco-Nephrology\n                      , Deputy Editor of\n                      Kidney360\n                      and AKI Series Editor of\n                      Clinical Nephrology\n                      . He serves on editorial boards for\n                      Kidney International\n                      ,\n                      KI Reports\n                      , the\n                      Journal of Nephrology\n                      and the\n                      American Journal of Medicine\n                      . D.R. served on advisory boards of Novartis and Alexion, had teaching honorariums from GSK, BMS, Roche, Novartis and Alexion, and is an\n                      UpToDate\n                      contributor. C.R. reports serving as Editor-in-Chief of\n                      Blood Purification and Cardiorenal Medicine\n                      and serving as speaker and having consultancy agreements with AstraZeneca, Aferetica, Asahi, Bayer, B. Braun, Baxter, bioM\u00e9rieux, CytoSorbents, GE, Medica and Jafron. E.S. acts as a consultant for D.E. Shaw Research and serves on the Advisory Board for Mallinckrodt Pharmaceuticals. B.S. is Theme Editor for onconephrology for the\n                      Clinical Kidney Journal\n                      and on the editorial board of the\n                      Journal of Onco-Nephrology and Glomerular Diseases\n                      . V.Tesa\u0159 is on the editorial board of the\n                      Clinical Kidney Journal\n                      and is Editor-in-Chief of\n                      Frontiers in Nephrology\n                      . He also served on the advisory board or received honoraria from AstraZeneca, Boehringer Ingelheim, Novartis, Otsuka, Travere and Vera. V.Torres serves as Academic Editor for\n                      PLoS One\n                      and is coordinator of the GFR Research Group of the American Society of Onconephrology. R.W. serves as an Associate Editor for the\n                      Journal of Onco-Nephrology\n                      and the\n                      Clinical Kidney Journal\n                      . B.T.W. serves as a consultant for Otsuka. D.Z.-O. reports research support from the NIH NCI R01CA291827, R01CA243014, R44CA268314, R44CA232954, R01DK138101. She has intellectual property with Galera Therapeutics and Perspective Therapeutics outside the submitted work. A.D.R., D.E.G., S.L., A.R., A.W. and M.H.R. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}